-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
November 01, 2010 - Evidence Report on the
Source: www.effectivehealthcare.ahrq.gov
Published Online: July 28, 2010
Evidence-based Practice Center Systematic Review Protocol
Project Title: Screening for and Management of Chronic Kidney
Disease Stages 1-3
I. Background and Objectives for the Systematic Review
T…
-
effectivehealthcare.ahrq.gov/products/diabetes-behavior-programs/research-protocol
June 05, 2014 - We will calculate mean differences or standardized mean differences for continuous variables, and risk … We will calculate pooled mean differences, standardized mean differences, risk ratios or odds ratios
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-afib-update_research-protocol-amended.pdf
October 27, 2017 - ranges from 0 to 6, with increasing
scores corresponding to increasing stroke risk, and is easy to calculate … ranges from 0 to 9, with increasing scores
corresponding to increasing stroke risk, and is easy to calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c-treatment-adherence_executive.pdf
September 22, 2011 - 1
Comparative Effectiveness Review
Number 91
Interventions To Improve Patient
Adherence to Hepatitis C Treatment:
Comparative Effectiveness
Executive Summary
Background
Hepatitis C virus (HCV) is the most
common chronic blood-borne infectious
disease in the United States.1,2 The Centers
for Disease Contro…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-kidney-disease-anemia-2011_executive.pdf
January 01, 2011 - 1
Comparative Effectiveness Review
Number 83
Biomarkers for Assessing and Managing
Iron Deficiency Anemia in Late-Stage
Chronic Kidney Disease
Executive Summary
Background
Chronic kidney disease (CKD) is
the gradual, progressive deterioration
of kidney function, and a condition
that affects an estimate…
-
effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
October 01, 2007 - population-based cohort
studies such as the Atherosclerotic Risk in Communities study
have produced tools to calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/plasma-cell-dyscrasias-sflc-assay_disposition-comments.pdf
August 23, 2012 - sensitivity and specificity, but we have included intervals
from the studies that provided enough data to calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_executive.pdf
March 01, 2012 - ethnicity, recent infection, and comorbidity were analyzed
if studies provided sufficient data to calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-strength-evidence.ppt
June 01, 2012 - PowerPoint Presentation
Grading the Strength of a Body of Evidence on Diagnostic Tests
Prepared for:
The Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Medical Test Reviews Methods Guide
www.ahrq.gov
Grading the Strength of a Body of Evidence on Diagnostic Tests
This slide set is based on c…
-
effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-strength-evidence.ppt
June 01, 2012 - PowerPoint Presentation
Grading the Strength of a Body of Evidence on Diagnostic Tests
Prepared for:
The Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Medical Test Reviews Methods Guide
www.ahrq.gov
Grading the Strength of a Body of Evidence on Diagnostic Tests
This slide set is based on c…